MiRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Aug 29

PMID 39204331

Authors

Mariia Toropko

Sergey Chuvpilo

Alexander Karabelsky

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression by inhibiting the translation of target transcripts. The expression profiles of miRNAs vary in different tissues and change with the development of diseases, including cancer. This feature has begun to be used for the modification of oncolytic viruses (OVs) in order to increase their selectivity and efficacy. OVs represent a relatively new class of anticancer drugs; they are designed to replicate in cancer tumors and destroy them. These can be natural viruses that can replicate within cancer tumor cells, or recombinant viruses created in laboratories. There are some concerns regarding OVs' toxicity, due to their ability to partially replicate in healthy tissues. In addition, lytic and immunological responses upon OV therapy are not always sufficient, so various OV editing methods are used. This review discusses the latest results of preclinical and clinical studies of OVs, modifications of which are associated with the miRNA-mediated mechanism of gene silencing.

Citing Articles

Recombinant VSVs: A Promising Tool for Virotherapy.

Vorona K, Moroz V, Gasanov N, Karabelsky A Acta Naturae. 2025; 16(4):4-14.

PMID: 39877014 PMC: 11771844. DOI: 10.32607/actanaturae.27501.

Cutting-Edge Advances in Anticancer Therapies: Insights from the Third Edition of the Special Issue "Novel Anticancer Strategies".

Bousbaa H Pharmaceutics. 2025; 17(1.

PMID: 39861702 PMC: 11769241. DOI: 10.3390/pharmaceutics17010054.

References

Wang N, Tan H, Feng Y, Zhang C, Chen F, Feng Y . microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance. Cancers (Basel). 2018; 11(1). PMC: 6356664. DOI: 10.3390/cancers11010007. View

Zhang K, Matsui Y, Lee C, Osamu O, Skinner L, Wang J . Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs. Gene Ther. 2016; 23(5):460-8. DOI: 10.1038/gt.2016.18. View

Landais I, Pelton C, Streblow D, DeFilippis V, McWeeney S, Nelson J . Human Cytomegalovirus miR-UL112-3p Targets TLR2 and Modulates the TLR2/IRAK1/NFκB Signaling Pathway. PLoS Pathog. 2015; 11(5):e1004881. PMC: 4425655. DOI: 10.1371/journal.ppat.1004881. View

Thakral S, Ghoshal K . miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 2014; 15(2):142-50. PMC: 4439190. DOI: 10.2174/1566523214666141224095610. View

Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

Long D, Lee R, Williams P, Chan C, Ambros V, Ding Y . Potent effect of target structure on microRNA function. Nat Struct Mol Biol. 2007; 14(4):287-94. DOI: 10.1038/nsmb1226. View

Zhao J, Zhou Y, Guo M, Yue D, Chen C, Liang G . MicroRNA-7: expression and function in brain physiological and pathological processes. Cell Biosci. 2020; 10:77. PMC: 7288475. DOI: 10.1186/s13578-020-00436-w. View

Guo Z, Maki M, Ding R, Yang Y, Zhang B, Xiong L . Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues. Sci Rep. 2014; 4:5150. PMC: 5381490. DOI: 10.1038/srep05150. View

Huang W, Wu X, Xiang S, Qiao M, Cen X, Pan X . Regulatory mechanism of miR-20a-5p expression in Cancer. Cell Death Discov. 2022; 8(1):262. PMC: 9110721. DOI: 10.1038/s41420-022-01005-5. View

10.

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

11.

PELNER L, Fowler G, NAUTS H . Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand Suppl. 1958; 338:1-47. View

12.

Lu Y, Zhang L, Waye M, Fu W, Zhang J . MiR-218 mediates tumorigenesis and metastasis: Perspectives and implications. Exp Cell Res. 2015; 334(1):173-82. DOI: 10.1016/j.yexcr.2015.03.027. View

13.

Mogilyansky E, Rigoutsos I . The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013; 20(12):1603-14. PMC: 3824591. DOI: 10.1038/cdd.2013.125. View

14.

Umbach J, Yen H, Poon L, Cullen B . Influenza A virus expresses high levels of an unusual class of small viral leader RNAs in infected cells. mBio. 2010; 1(4). PMC: 2934610. DOI: 10.1128/mBio.00204-10. View

15.

Mahmoudi E, Cairns M . MiR-137: an important player in neural development and neoplastic transformation. Mol Psychiatry. 2016; 22(1):44-55. PMC: 5414082. DOI: 10.1038/mp.2016.150. View

16.

Zhang J, Liu L, Xu T, Zhang W, Li J, Rao N . Time to infer miRNA sponge modules. Wiley Interdiscip Rev RNA. 2021; 13(2):e1686. DOI: 10.1002/wrna.1686. View

17.

Yu H, Lu Y, Li Z, Wang Q . microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr Drug Targets. 2014; 15(9):817-28. DOI: 10.2174/1389450115666140627104151. View

18.

Jopling C . Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012; 9(2):137-42. PMC: 3346312. DOI: 10.4161/rna.18827. View

19.

Otani Y, Yoo J, Chao S, Liu J, Jaime-Ramirez A, Lee T . Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition. Clin Cancer Res. 2020; 26(10):2381-2392. PMC: 7325527. DOI: 10.1158/1078-0432.CCR-19-3420. View

20.

Geoffroy K, Bourgeois-Daigneault M . The pros and cons of interferons for oncolytic virotherapy. Cytokine Growth Factor Rev. 2020; 56:49-58. DOI: 10.1016/j.cytogfr.2020.07.002. View